Calithera Biosciences, Inc. (CALA) Analysts See $-0.24 EPS

February 23, 2018 - By Peter Erickson

 Calithera Biosciences, Inc. (CALA) Analysts See $ 0.24 EPS
Investors sentiment decreased to 1.22 in Q3 2017. Its down 2.03, from 3.25 in 2017Q2. It worsened, as 16 investors sold Calithera Biosciences, Inc. shares while 21 reduced holdings. 14 funds opened positions while 31 raised stakes. 25.24 million shares or 49.47% less from 49.95 million shares in 2017Q2 were reported.
Lord Abbett Ltd Liability reported 630,261 shares. Panagora Asset Mgmt accumulated 184,310 shares or 0.01% of the stock. Barclays Public Limited has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). 52 were reported by Meeder Asset Management. Morgan Stanley accumulated 60,262 shares or 0% of the stock. Acadian Asset Mgmt Limited Liability holds 1,572 shares. Clarivest Asset Management Ltd Liability has invested 0.02% in Calithera Biosciences, Inc. (NASDAQ:CALA). New York State Common Retirement Fund stated it has 32,700 shares or 0% of all its holdings. Franklin Res owns 750,000 shares or 0.01% of their US portfolio. 23,222 were reported by Iconiq Limited. Citadel Advsr Ltd Company reported 480,673 shares or 0.01% of all its holdings. Gam Ag owns 40,200 shares or 0.03% of their US portfolio. Royal Fincl Bank Of Canada stated it has 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Geode Capital Mngmt Limited stated it has 292,820 shares or 0% of all its holdings. 4,600 are owned by Macquarie Grp.

Analysts expect Calithera Biosciences, Inc. (NASDAQ:CALA) to report $-0.24 EPS on March, 15.They anticipate $0.21 EPS change or 46.67 % from last quarter’s $-0.45 EPS. After having $-0.17 EPS previously, Calithera Biosciences, Inc.’s analysts see 41.18 % EPS growth. The stock decreased 0.62% or $0.05 during the last trading session, reaching $8.05. About 378,292 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 278.82% since February 23, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.

Calithera Biosciences, Inc. (NASDAQ:CALA) Ratings Coverage

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calithera Biosciences had 10 analyst reports since July 24, 2015 according to SRatingsIntel. As per Tuesday, January 24, the company rating was upgraded by Citigroup. The rating was upgraded by Citigroup to “Buy” on Friday, February 16. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. H.C. Wainwright maintained the shares of CALA in report on Monday, June 12 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Thursday, January 5. Citigroup initiated it with “Buy” rating and $11 target in Friday, July 24 report. The firm has “Buy” rating given on Tuesday, March 28 by H.C. Wainwright. The firm has “Sell” rating by Citigroup given on Tuesday, October 25.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $285.59 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Another recent and important Calithera Biosciences, Inc. (NASDAQ:CALA) news was published by Fool.com which published an article titled: “Here’s Why Calithera Biosciences, Inc. Rose as Much as 25.2% Today” on February 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: